Safety, tolerability and pharmacokinetics (PKs) of multiple oral doses of GR3027 in healthy male volunteers and single and multiple doses in patients with cirrhosis. Preliminary efficacy in cirrhotic patients with evidence of covert hepatic encephalopathy (CHE). A prospective, double-blinded, randomized, placebo-controlled phase I/IIa study.

Trial Profile

Safety, tolerability and pharmacokinetics (PKs) of multiple oral doses of GR3027 in healthy male volunteers and single and multiple doses in patients with cirrhosis. Preliminary efficacy in cirrhotic patients with evidence of covert hepatic encephalopathy (CHE). A prospective, double-blinded, randomized, placebo-controlled phase I/IIa study.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs GR 3027 (Primary)
  • Indications Hepatic encephalopathy
  • Focus Adverse reactions
  • Sponsors Umecrine Cognition
  • Most Recent Events

    • 04 Oct 2017 According to a Karolinska Development media release, phase 1b portion of this trial is completed.
    • 13 Sep 2017 According to a Karolinska Development media release, results of phase 2a portion expected during 2018 .
    • 13 Sep 2017 Results from Phase Ib portion (n=18) published in the Karolinska Development Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top